New effective antitumor agents targeting the EGFR are necessary due to their significance in cancer treatment, leading to the creation of imidazolone-sulphonamide-pyrimidine hybrids as analogs to existing EGFR inhibitors.
Among the synthesized compounds, 4-(Furan-2-ylmethylene)imidazolone-sulphonamide-pyrimidine 6b displayed the strongest cytotoxicity against breast cancer MCF-7 cells, with an IC value of 1.05 μM, outperforming the standard treatment doxorubicin.
The studies indicated that compound 6b not only inhibits EGFR kinase but also causes MCF-7 cells to arrest at the G1 phase